Entering text into the input field will update the search result below

Repros Therapeutics jumps as Androxal meets endpoints

Sep. 17, 2013 8:30 AM ETRoyalty Pharma plc (RPRX) StockRPRX-OLDBy: Colin Lokey, SA News Editor
  • Repros Therapeutics (NASDAQ:RPRX) soars 26% premarket.
  • Androxal topline results from ZA-302 (pivotal efficacy) and ZA-300 (six-month safety) show the secondary hypogonadism treatment met both primary endpoints and is generally well tolerated.
  • ZA-302 results are "almost identical" to the first pivotal efficacy study. (PR)
  • Expect an NDA in mid-2014.
  • RPRX says it expects to have "launch drug product available for an anticipated approval during 2015."
  • It's worth noting that back in July, BofA's Steve Byrne said peak 2022 sales could reach $450M.

Recommended For You

More Trending News

About RPRX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
RPRX--
Royalty Pharma plc
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.